LAS VEGAS (FOX5) — An even more powerful drug could be on the horizon to treat obesity and type 2 diabetes. Retatrutide, nicknamed GLP-3, is an investigational drug that activates three hormone receptors instead of two that regulate appetite and metabolism.
“What retatrutide is looking for is that it’s going to have a glucagon pathway. And glucagon is going to increase how much your body expends energy. And so not only are you changing how much you’re taking in through your appetite, but you’re also using a little bit more energy,” said Evan Williams, professor at Roseman University of Health Sciences College of Pharmacy.
Clinical trial results
The experimental drug is currently in late-stage clinical trials. It is not FDA-approved.
Some study volunteers lost an average of 70 pounds over 18 months, according to data from the drug’s manufacturer…